(Length of Discussion: 12 min)

Stefano Fanti shares his views of the use of imaging in prostate cancer and where it most useful. This conversations includes discussion on the rapidly developing area of PSMA PET and the clinical implications including  in biochemical reoccurrence, targeted radiation and identifying high risk diseases for patients with potential oligometastatic disease. Other key points discussed are concerns of false positive results and the learning curve of new tracers, as well as the direction and future of tracers for the treatment of prostate cancer. 

Biographies:

Stefano Fanti, Professor Department of Experimental, Diagnostic and Specialty Medicine - DIMES  at the University of Bologna.  He is Director of Nuclear Medicine Division of the PET Unit at the Policlinico S. Orsola and Director of Speciality School of Nuclear Medicine at University of Bologna.

Alicia Morgans, MD, MPH.

Related Content:
Watch: Oligometastatic and Oligo-progressive Prostate Cancer: Answer of the Nuclear Specialist - Stefano Fanti